Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pyrazinamide

FDA-approved product (tablet, oral), marketed as Pyrazinamide.

Registered studies
50+
Lab records
45
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Pyrazinamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for treatment of tuberculosis
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AK01; FDA class Antimycobacterial

Repurposing investigation

Pyrazinamide is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli15.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae7.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis13.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 2 of 45 lab records
Open Pyrazinamide in ChEMBL Registered studies below
Show the 45 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-4.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pyrazinamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults

    NCT05283967 · start 2019-01-01

    Registered record
    Registry ID
    NCT05283967
    Conditions
    Tuberculosis
    Interventions
    urine colorimetric assay
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-01-01
    Completion
    2023-12-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionurine colorimetric assay
    PhaseNot recorded
    Registry statusCompleted

  • Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis

    NCT03478033 · start 2018-04-15

    Registered record
    Registry ID
    NCT03478033
    Conditions
    Tuberculosis, Pulmonary; AIDS
    Interventions
    Rifampicin; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-04-15
    Completion
    2020-12-31
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; AIDS
    InterventionRifampicin; Rifabutin
    PhaseNot applicable
    Registry statusUnknown

  • The Individualized M(X) Drug-resistant TB Treatment Strategy Study

    NCT03237182 · start 2017-06-14

    Registered record
    Registry ID
    NCT03237182
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Individualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-06-14
    Completion
    2022-12-19
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionIndividualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    PhasePhase 4
    Registry statusTerminated

  • Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

    NCT02901288 · start 2016-08

    Registered record
    Registry ID
    NCT02901288
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Isoniazid; Rifampicin; Pyrazinamide; Ethambutol; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-08
    Completion
    2018-12
    Enrolment
    3,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionIsoniazid; Rifampicin; Pyrazinamide; Ethambutol +1 more
    PhasePhase 4
    Registry statusUnknown

  • The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

    NCT02409290 · start 2016-03

    Registered record
    Registry ID
    NCT02409290
    Conditions
    MDR-TB
    Interventions
    Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline); Moxifloxacin; Clofazimine; Ethambutol; Pyrazinamide; Isoniazid; Prothionamide; Kanamycin; Levofloxacin; Bedaquiline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-03
    Completion
    2023-05-02
    Enrolment
    588

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMDR-TB
    InterventionRegimen A locally-used WHO-approved MDR-TB regimen (2011 guideline); Moxifloxacin; Clofazimine; Ethambutol +6 more
    PhasePhase 3
    Registry statusCompleted

  • Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers

    NCT02700347 · start 2016-02

    Registered record
    Registry ID
    NCT02700347
    Conditions
    Tuberculosis
    Interventions
    Pyrazinamide; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02
    Completion
    2016-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPyrazinamide; Allopurinol
    PhasePhase 1
    Registry statusCompleted

  • TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

    NCT02410772 · start 2016-01-25

    Registered record
    Registry ID
    NCT02410772
    Conditions
    Tuberculosis
    Interventions
    rifapentine; rifapentine and moxifloxacin; control
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-05
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionrifapentine; rifapentine and moxifloxacin; control
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

    NCT02563327 · start 2016-01-25

    Registered record
    Registry ID
    NCT02563327
    Conditions
    Tuberculosis
    Interventions
    Rifapentine; Moxifloxacin; Rifampin; Isoniazid; Pyrazinamide; Ethambutol; Pyridoxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-08-30
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine; Moxifloxacin; Rifampin; Isoniazid +3 more
    PhasePhase 3
    Registry statusCompleted

  • Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers

    NCT02602509 · start 2015-11

    Registered record
    Registry ID
    NCT02602509
    Conditions
    Tuberculosis
    Interventions
    Celecoxib; Rifampicin; Pyrazinamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-11
    Completion
    2016-02
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionCelecoxib; Rifampicin; Pyrazinamide
    PhasePhase 1
    Registry statusCompleted

  • Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

    NCT01601626 · start 2013-07-13

    Registered record
    Registry ID
    NCT01601626
    Conditions
    HIV Infection; Tuberculosis
    Interventions
    Standard-dose Lopinavir/Ritonavir; Double-dose Lopinavir/Ritonavir; Raltegravir; Isoniazid; Pyridoxine; Pyrazinamide; Ethambutol; Rifabutin; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-07-13
    Completion
    2017-06-28
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Tuberculosis
    InterventionStandard-dose Lopinavir/Ritonavir; Double-dose Lopinavir/Ritonavir; Raltegravir; Isoniazid +5 more
    PhasePhase 2
    Registry statusTerminated

  • Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes

    NCT01782950 · start 2013-02

    Registered record
    Registry ID
    NCT01782950
    Conditions
    AIDS With Tuberculosis
    Interventions
    Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-02
    Completion
    2016-03
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAIDS With Tuberculosis
    InterventionRifampicin, Isoniazid, Ethambutol, Pyrazinamide
    PhasePhase 4
    Registry statusUnknown

  • A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults

    NCT01399788 · start 2011-07

    Registered record
    Registry ID
    NCT01399788
    Conditions
    Healthy Volunteers
    Interventions
    Myrin P Forte; Single drug references
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-07
    Completion
    2011-08
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionMyrin P Forte; Single drug references
    PhasePhase 1
    Registry statusCompleted

  • Study of Rifampicin in Multiple System Atrophy

    NCT01287221 · start 2011-03

    Registered record
    Registry ID
    NCT01287221
    Conditions
    Multiple System Atrophy
    Interventions
    Rifampicin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-03
    Completion
    2013-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple System Atrophy
    InterventionRifampicin; placebo
    PhasePhase 3
    Registry statusTerminated

  • Anti-tuberculosis (TB) Drug Levels and Correlation With Drug Induced Hepatotoxicity

    NCT01456845 · start 2010-08

    Registered record
    Registry ID
    NCT01456845
    Conditions
    Hepatitis; Tuberculosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2012-06
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis; Tuberculosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis

    NCT00728507 · start 2009-11

    Registered record
    Registry ID
    NCT00728507
    Conditions
    Tuberculosis
    Interventions
    Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Isoniazid, Rifampin, Pyrazinamide, Ethambutol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-11
    Completion
    2013-04
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Isoniazid, Rifampin, Pyrazinamide, Ethambutol
    PhasePhase 2
    Registry statusTerminated